Stephen Hoge Sells 255 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) President Stephen Hoge sold 255 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $120.96, for a total transaction of $30,844.80. Following the sale, the president now directly owns 1,486,508 shares of the company's stock, valued at $179,808,007.68. The sale was disclosed in a document filed with the SEC, which is available through this link.

Stephen Hoge also recently made the following trade(s):

• On Monday, April 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $105.02, for a total transaction of $1,575,300.00.
• On Thursday, February 29th, Stephen Hoge sold 2,388 shares of Moderna stock. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16.

Moderna Trading Up 7.1 %

Shares of MRNA traded up $8.36 during mid-day trading on Monday, reaching $125.67. 4,093,683 shares of the company's stock traded hands, compared to its average volume of 4,103,305. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The stock's 50-day moving average is $108.24 and its two-hundred day moving average is $96.29. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79. The stock has a market cap of $48.16 billion, a P/E ratio of -8.02 and a beta of 1.57.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same quarter in the prior year, the company posted $0.19 EPS. Moderna's quarterly revenue was down 91.0% on a year-over-year basis. Research analysts forecast that Moderna, Inc. will post -7.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MRNA shares. Jefferies Financial Group reaffirmed a "buy" rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Canaccord Genuity Group upped their price objective on Moderna from $91.00 to $106.00 and gave the stock a "hold" rating in a report on Friday, May 3rd. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a research report on Thursday, May 2nd. Royal Bank of Canada boosted their price target on shares of Moderna from $125.00 to $135.00 and gave the stock an "outperform" rating in a research report on Friday, May 3rd. Finally, HSBC reiterated a "reduce" rating and set a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $126.89.

Institutional Investors Weigh In On Moderna

Large investors have recently added to or reduced their stakes in the stock. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna during the fourth quarter valued at approximately $27,000. Arlington Trust Co LLC increased its holdings in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company's stock worth $29,000 after purchasing an additional 290 shares during the period. Cedar Wealth Management LLC raised its position in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock valued at $31,000 after purchasing an additional 90 shares in the last quarter. Westside Investment Management Inc. purchased a new stake in shares of Moderna in the 1st quarter worth $32,000. Finally, Rise Advisors LLC grew its position in shares of Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company's stock worth $34,000 after buying an additional 286 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.